NR2F2 and prostate adenocarcinoma: COUP-TFII (NR2F2) promotes prostate tumorigenesis by inhibiting TGF-β-induced growth barriers and correlates with increased lymphangiogenesis and lymph node metastasis in prostate adenocarcinoma [26, 27].